Total body and spinal bone mineral density across Tanner stage in perinatally HIV-infected and uninfected children and youth in PACTG 1045

AIDS

Volumn 24, Issue 5, 2010, Pages 687-696

  Jacobson, Denise L ^a   Lindsey, Jane C ^a   Gordon, Catherine M ^b   Moye, Jack ^c   Hardin, Dana S ^d   Mulligan, Kathleen ^e   Aldrovandi, Grace M ^f  

^a CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^d NATIONWIDE CHILDREN S HOSPITAL   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

Antiretroviral; Bone mass; Children; DXA; Perinatal HIV infection; Tanner stage

Indexed keywords

ANTIRETROVIRUS AGENT; CALCIUM; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; VITAMIN D; ZIDOVUDINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; BODY HEIGHT; BONE; BONE DENSITY; BONE MASS; BONE MINERAL; CHILD; CONTROLLED STUDY; DEMOGRAPHY; DIET SUPPLEMENTATION; DISEASE DURATION; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; ETHNICITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JUVENILE; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERINATAL PERIOD; PRIORITY JOURNAL; PUBERTY; RACE DIFFERENCE; RISK FACTOR; SCHOOL CHILD; SOCIAL ASPECT; SPINE;

ABSORPTIOMETRY, PHOTON; ADOLESCENT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BONE DENSITY; CHILD; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; LINEAR MODELS; MALE; PUBERTY; SEX FACTORS; SPINE; YOUNG ADULT;

EID: 77949413091     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328336095d     Document Type: Article

References (47)

1. Arpadi SM, Horlick M, Thornton J, Cuff PA, Wang J, Kotler DP. Bone mineral content is lower in prepubertal HIV-infected children. J Acquir Immune Defic Syndr 2002; 29:450-454.
2. O'Brien KO, Razavi M, Henderson RA, Caballero B, Ellis KJ. Bone mineral content in girls perinatally infected with HIV. Am J Clin Nutr 2001; 73:821-826.
3. Mora S, Zamproni I, Beccio S, Bianchi R, Giacomet V, Vigano A. Longitudinal changes of bone mineral density and metabolism in antiretroviral-treated human immunodeficiency virus-infected children. J Clin Endocrinol Metab 2004; 89:24-28.
4. Jacobson DL, Spiegelman D, Duggan C, Weinberg GA, Bechard L, Furuta L, et al. Predictors of bone mineral density in human immunodeficiency virus-1 infected children. J Pediatr Gastro-enterol Nutr 2005; 41:339-346.
5. Amorosa V, Tebas P. Bone disease and HIV infection. Clin Infect Dis 2006; 42:108-114.
6. Burnham JM, Shults J, Semeao E, Foster B, Zemel BS, Stallings VA, et al. Whole body BMC in pediatric Crohn disease: independent effects of altered growth, maturation, and body composition. J Bone Miner Res 2004; 19:1961-1968.
7. Burnham JM, Shults J, Dubner SE, Sembhi H, Zemel BS, Leonard MB. Bone density, structure, and strength in juvenile idiopathic arthritis: importance of disease severity and muscle deficits. Arthritis Rheum 2008; 58:2518-2527.
8. Dubner SE, Shults J, Baldassano RN, Zemel BS, Thayu M, Burnham JM, et al. Longitudinal assessment of bone density and structure in an incident cohort of children with Crohn's disease. Gastroenterology 2009; 136:123-130.
9. de Martino M, Tovo P, Galli L, Gabiano C, Chiarelli F, Zappa M, et al. Puberty in perinatal HIV-1 infection: a multicentre longitudinal study of 212 children. AIDS 2001; 15:1527-1534.
10. Miller TL, Evans SJ, Orav EJ, McIntosh K, Winter HS. Growth and body composition in children infected with the human immunodeficiency virus-1. Am J Clin Nutr 1993; 57:588-592.
11. Chantry CJ, Byrd RS, Englund JA, Baker CJ, McKinney RE. Pediatric AIDS Clinical Trials Group Protocol 152 Study Team. Growth, survival and viral load in symptomatic childhood human immunodeficiency virus infection. Pediatr Infect Dis J 2003; 22:1033-1038.
12. Gafni RI, Hazra R, Reynolds JC, Maldarelli F, Tullio A, DeCarlo E, et al. Decreased bone density (BMD) in HIV-infected children treated with tenofovir disoproxil fumarate (TDF)-contain-ing HAART. Pediatr Res 2004; 55:329A-1329A.
13. Fernandez-Rivera J, Garcia R, Lozano F, Macias J, Garcia-Garcia JA, Mira JA, et al. Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients. HIV Clin Trials 2003; 4:337-346.
14. Theintz G, Buchs B, Rizzoli R, Slosman D, Clavien H, Sizonenko PC, et al. Longitudinal monitoring of bone mass accumulation in healthy adolescents: evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects. J Clin Endocrinol Metab 1992; 75:1060-1065.
15. Rizzoli R, Bonjour JP. Determinants of peak bone mass and mechanisms of bone loss. Osteoporos Int 1999; 9 (Suppl 2):S17-23.
16. Gordon CM, Bachrach LK, Carpenter TO, Crabtree N, El-Hajj Fuleihan G, Kutilek S, et al. Dual energy X-ray absorptiometry interpretation and reporting in children and adolescents: the 2007 ISCD Pediatric Official Positions. J Clin Densitom 2008; 11:43-58.
17. Saggese G, Baroncelli GI, Bertelloni S. Puberty and bone development. Best Pract Res Clin Endocrinol Metab 2002; 16:53-64.
18. Loud KJ, Gordon CM. Adolescent bone health. Arch Pediatr Adolesc Med 2006; 160:1026-1032.
19. Finkelstein JS, Klibanski A, Neer RM. A longitudinal evaluation of bone mineral density in adult men with histories of delayed puberty. J Clin Endocrinol Metab 1996; 81:1152-1155.
20. Hansen MA, Overgaard K, Riis BJ, Christiansen C. Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. BMJ 1991; 303:961-964.
21. Aldrovandi GM, Lindsey JC, Jacobson DL, Zadzilka A, Sheeran E, Moye J, et al. Morphologic and metabolic abnormalities in vertically HIV-infected children and youth. AIDS 2009; 23:661-672.
22. Panel on Dietary Antioxidants and Related Compounds, Subcommittees on Upper Reference Levels of Nutrients and Interpretation and Uses of Dietary Reference Intakes, and the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. Summary. In Dietary reference intakes for vitamin C, vitamin E, selenium, and carotenoids. Washington, D.C.: National Academy Press; 2000. pp.1-20.
23. Turnbull BW. The empirical distribution function with arbitrarily grouped, censored and truncated data. J Royal Statist Soc Series B 1976; 38:290-295.
24. Collett D. Modelling survival data in medical research. London: Chapman and Hall; 1994.
25. Katzman DK, Bachrach LK, Carter DR, Marcus R. Clinical and anthropometriccorrelatesofbonemineralacquisitioninhealthy adolescent girls. J Clin Endocrinol Metab 1991; 73:1332-1339.
26. Arpadi S, Horlick M, Shane E. Metabolic bone disease in human immunodeficiency virus-infected children. J Clin Endocrinol Metab 2004; 89:21-23.
27. Tan BM, NelsonRP, James-YarishM,Emmanuel PJ, Schurman SJ. Bone metabolism in children with human immunodeficiency virus infection receiving highly active antiretroviral therapy including a protease inhibitor. J Pediatr 2001; 139:447-451.
28. Seeman E. Clinical review 137: sexual dimorphism in skeletal size, density, and strength. J Clin Endocrinol Metab 2001; 86:4576-4584.
29. Seeman E. The structural and biomechanical basis of the gain and loss of bone strengthinwomen and men. Endocrinol Metab Clin North Am 2003; 32:25-38.
30. Seeman E. Periosteal bone formation: a neglected determinant of bone strength. N Engl J Med 2003; 349:320-323.
31. Cazanave C, Dupon M, Lavignolle-Aurillac V, Barthe N, Lawson-Ayayi S, Mehsen N, et al. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS 2008; 22:395-402.
32. Guaraldi G, Roverto A, Garlassi E, Zirilli L. Gender and gonadal function difference in the prevalence of bone mass reduction. CROI 2009.
33. Jacobson DL, Spiegelman D, Knox TK, Wilson IB. Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study. J Acquir Immune Defic Syndr 2008; 49:298-308.
34. Mahoney EM, Donfield SM, Campbell H, Kaufman F, Gertner JM, Hemophilia Growth Development Study. HIV-associated immune dysfunction and delayed pubertal development in a cohort of young hemophiliacs. J Acquir Immune Defic Syndr 1999; 21:333-337.
35. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006; 20:2165-2174.
36. Tebas P, Zhang J, Yarasheski K, Evans S, Fischl MA, Shevitz A, et al. Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125 s). J Acquir Immune Defic Syndr 2007; 45:193-200.
37. Nolan D, Upton R, McKinnon E, John M, James I, Adler B, et al. Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS 2001; 15:1275-1280.
38. Dube MP, Qian DJ, Edmondson-Melancon H, Sattler FR, Goodwin D, Martinez C, et al. Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. Clin Infect Dis 2002; 35:475-481.
39. Mondy K, Yarasheski K, Powderly WG, Whyte M, Claxton S, DeMarco D, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 2003; 36:482-490.
40. Tebas P, YarasheskiK, Henry K, Claxton S, Kane E, Bordenave B, et al. Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection. AIDS Res Hum Retrovir 2004; 20:589-594.
41. Wang MW, Wei S, Faccio R, Takeshita S, Tebas P, Powderly WG, et al. The HIV protease inhibitor ritonavir blocks osteo-clastogenesis and function by impairing RANKL-induced signaling. J Clin Invest 2004; 114:206-213.
42. Favus MJ. Primer on the metabolic bone diseases and disorders of mineral metabolism. Washington: Amercian Society for Bone and Mineral Research; 2003.
43. Pan G, Wu X, McKenna MA, Feng X, Nagy TR, McDonald JM. AZT enhances osteoclastogenesis and bone loss. AIDS Res Hum Retroviruses 2004; 20:608-620.
44. Van Vonderen MGA, Lips P, van Agtmael MA, Hassink EAM, Brinkman K, Geerlings SE, et al. First line zidovudine/lami-vudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. AIDS 2009; 23:1367-1376.
45. Gallant JE, Staszewski S, Pozniak AI, deJesus E, Suleiman JMAH, Miller MD, et al. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naive patients. JAMA 2004; 292:191-201.
46. Pitukcheewanont P, Safani D, Church J, Gilsanz V. Bone measures in HIV-1 infected children and adolescents: disparity between quantitative computed tomography and dual-energy X-ray absorptiometry measurements. Osteoporos Int 2005; 16:1393-1396.
47. ZemelB, BassS, BinkleyT, DucherG,Macdonald H, McKay H, et al. Peripheral quantitative computed tomography in children and adolescents: the 2007 ISCD Pediatric Official Positions. J Clin Densitom 2008; 11:59-74.